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NigeriaBackground: Early identification of determinants of tuberculosis (TB) treatment failure is
urgently needed in resource-limited settings. This study describes the profile and determi-
nants of TB treatment failure in a high-incidence setting where patients were managed at a
TB control program with significant resource limitations.
Methods: This was a retrospective case-control study carried out in one tertiary and one
secondary hospital in Southeastern Nigeria. Cases were adult (P15 years) TB patients with
a positive sputum smear after 5 months of treatment (treatment failure). Controls were
adult TB patients whose sputum smear was positive at the beginning of the treatment
but who were smear-negative in the last month of treatment and on at least one previous
occasion (cured). Cases were compared with controls to assess determinants of treatment
failure.
Results: Of the 1668 TB patients registered during the study period, 985 (59%) had smear-
positive pulmonary TB. Of these, 694 (70.5%) were aged 640 years, 602 (61.1%) were males,
707 (71.8%) were rural residents, and 898 (91.2%) received care at the private facility. The
prevalence of treatment failure was 2.5%. Significant determinants of treatment failure
were: older age (>40 years) (P < 0.001), male gender (P = 0.04), previous treatment for TB
(P = 0.045), and positive sputum smears after two month of anti-tuberculosis treatment
(0.001).
Conclusion: This study showed that the treatment failure rate among smear-positive TB
patients is low in Nigeria. Education and improved clinical and laboratory interventions
for the identified at-risk groups may reduce TB treatment failure in resource-limited
settings.
 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction
Tuberculosis (TB) control remains a global challenge espe-
cially in high-burden countries where resources are limited,human immunodeficiency virus (HIV) co-infection is high,
and control efforts are being threatened by drug-resistant
TB [1,2]. The World Health Organisation (WHO) currently
recommends a case detection rate of 70% and a treatment
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achieving these targets will lead to a reduction in TB preva-
lence, incidence, transmission and drug resistance to TB [3].
An important indicator recommended by the WHO for the
monitoring of TB control efforts is the proportion of pulmon-
ary TB patients whose sputum smear or culture are positive
after 5 months or later during treatment [4]. These individuals
are classified as treatment failure cases. Treatment failure is a
serious problem for National TB control programs because
cases tend to have higher morbidity and mortality compared
with those who are cured [5]. Also, they remain infectious for
prolonged periods of time; hence, affected patients continue
to transmit the disease in the community [5]. In addition, very
high rates of multidrug-resistant TB have been found among
treatment failure cases in resource-limited settings [6].
The identification of factors associated with treatment
failure is a priority for TB control programs because this
may help in the early institution of interventions for at-risk
TB patients in order to improve treatment targets [4]. Few
studies done in other settings have shown that predictors of
treatment failure may include social, radiological, laboratory
and treatment-related factors [7–10]. As these factors can vary
in different populations and health systems, it is important to
assess the situation in specific settings. No study has been
carried out to identify the determinants of treatment failure
in this setting. This study is aimed at determining the burden
and predictors of TB treatment failure in smear-positive pul-
monary TB patients in Southeastern Nigeria.Materials and methods
Study design and setting
The study was conducted in one tertiary (public) and one sec-
ondary (private/not-for-profit mission) hospital in Ebonyi
State, Southeastern Nigeria. A retrospective unmatched
case-control study design was used to assess adult smear-
positive pulmonary TB patients who registered for treatment
at the study sites between 1 January 2011 and 31 December
2012. Cases were smear-positive pulmonary TB aged
P15 years who had a positive sputum smear at 5 months
and were classified as treatment failure after treatment
(cases). Controls were adult pulmonary TB patients whose
sputum smear was positive at the beginning of the treatment,
but who were smear-negative in the last month of treatment
and on at least one previous occasion [11,12].
Diagnosis and treatment of TB and HIV
Adult patients suspected of having TB undergo sputum acid-
fast-bacilli (AFB) microscopy [11,12]. Patients with AFB in at
least one of the three smears submitted are registered as
smear-positive pulmonary TB. All adults suspected of having
TB undergo HIV counseling and testing at the time of submis-
sion of sputum for AFB [12]. The NTP in Ebonyi State phased
out the 8-month anti-TB regimen (consisting of 2 months of
rifampicin [R], isoniazid [H], pyrazinamide [Z] and ethambutol
[E]/6 months of ethambutol and isoniazid [2RHZE/6EH]) in the
2011 cohort [12]. All adult TB patients diagnosed in 2012 weretreated using the 6-month anti-tuberculosis regimen consist-
ing of: 2-month RHZE/and 4-month RH [2RHZE/4RH]. All the
patients receive community directly observed treatment short
course (DOTS). All HIV-infected TB patients are offered tri-
methoprim/sulfamethoxazole (cotrimoxazole prophylactic
treatment [CPT]) to prevent other opportunistic infections.
HIV treatment follows national andWHOguidelineswith anti-
retroviral therapy initiated between two weeks and two
months of commencing anti TB treatment [12].
Data collection and analysis
Using a standardized form, data about all smear-positive TB
patients treated at the participating centers were extracted.
Information collected included: registration status; age; gen-
der; residence; regimen received; and treatment outcome.
The standard WHO definitions were used for TB disease clas-
sification, registration and treatment outcome categories
(cured, completed treatment, failure, defaulted treatment,
died and transferred out) [11,12]. TB registration status was
divided into ‘new’ or ‘previously treated’.
Statistical analyses were performed using Epi Info (Epi Info
version 3.4.1; Centers for Disease Control and Prevention,
Atlanta, GA, USA). Univariate analyses were performed to de-
scribe the baseline characteristics of the participants and
were reported as proportions and means. Categorical groups’
comparisons were performed using the Chi-square tests, and
the Fisher’s exact test was used for an expected cell value fre-
quency less than five. Multivariable logistic regression analy-
sis showed unstable models and were therefore excluded. AP
value of <0.05 was considered significant.
The study was approved by the Ethics and Research Advi-
sory Committee of the National Tuberculosis and Leprosy
Control Programme, Ministry of Health, Ebonyi State.Results
Of the 1668 TB patients registered during the study period, 985
(59%) had smear-positive pulmonary TB. Of these, 694 (70.5%)
were aged 640 years, 602 (61.1%) were males, 707 (71.8%) were
rural residents and 898 (91.2%) received care at the private
facility. Also, 928 (94.2%) of the cases were registered as new
cases, 470 (47.7%) were treated with the current 6-month rif-
ampicin containing regimen, and 136 (13.8%) were HIV posi-
tive (Table 1). Overall, 797 (80.9%) of the participants were
cured, 98 (9.9%) defaulted, 57 (5.8%) died, 25 (2.5%) had treat-
ment failure, and 8 (0.8%) were transferred out.
Serial sputum AFB results of the study participants are
shown in Table 2; 985 patients were sputum smear-positive
at entry, and of these, 187 (19%) were smear-positive after
intensive treatment with RHZE for two months, and 25
(2.5%) remained positive after 5 months of treatment. There-
fore, the prevalence of treatment failure was 2.5% (proportion
with a positive sputum smear after 5 months of treatment).
The treatment failure rate among patients who were HIV po-
sitive was 5/131 (3.7%) compared with 20/849 (2.4%) among
those that were HIV negative (p = 0.36).
The analysis of factors associated with treatment failure is
as shown in Table 3. The predictors of treatment failure were:
Table 1 – Baseline characteristics of 985 patients with
smear-positive tuberculosis who were treated at the study
sites in Ebonyi State, Nigeria 2011–2012.
Characteristics Number Percent (%)
Age (years)
640 694 70.5
>40 291 29.5
Gender
Female 383 38.9
Male 602 61.1
Residence
Urban 278 28.2
Rural 707 71.8
Facility
Public 87 8.8
Private 898 91.2
Classification
New 928 94.2
Previously treated 57 5.8
Regimen
2RHZE/6EH 515 52.3
2RHZE/4RH 470 47.7
HIV Status
Positive 136 13.8
Negative 849 86.2
Treatment Outcome
Cured 797 80.9
Defaulted 98 9.9
Died 57 5.8
Failed 25 2.5
Transferred-out 8 0.8
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ous treatment for TB (p = 0.045) and positive sputum smears
after two months of anti-tuberculosis treatment (p = 0.001).
Discussion
In this study, it was shown that TB affects mainly the young
age group in this setting unlike high-income settings where
the elderly are the mostly affected group [13]. This finding
has been demonstrated in other resource-limited settings,
and it has a negative impact on the economy as a substantial
proportion of the workforce are not strong enough to contrib-
ute to socio-economic development. Also, a higher proportion
of patients with smear-positive were males; this agrees with
findings in northeastern and southwestern Nigeria [8,14]
and indicates the need to improve diagnosis of TB among
women.Table 2 – Serial sputum smear results of the study participants
Sputum AFB Result At registration n (%)
Positive 985 (100)
Negative 0
Total 985 (100)The cure rate of 80.9% in these patients was below the 85%
target recommended by the WHO guidelines [11]. This sug-
gests that more efforts are needed to further improve the
treatment success rate of TB care in this setting. This will re-
quire reducing the default rate and the mortality rates in this
region. The treatment failure rate in this study was 2.5%; this
agrees with the findings in Egypt where the treatment failure
ranged between 0.9% and 5.1% but was lower than a failure
rate of 5% and 22.6% found in tertiary hospital settings in
southwestern and northwestern Nigeria respectively [7,8,14].
In this study, it was shown that older age was a determi-
nant for treatment failure. This was unlike findings from
Uganda and Egypt which showed no differences in age [7,9].
The reasons for these differences are not clear. However, old-
er TB patients has been suggested to be at risk of increased
physical disability resulting in increased delay in clearing
the Mycobacterium bacilli probably due to decreasing immu-
nity and also delay in seeking care and diagnosis whichmight
lead to worsening of the disease [15]. Also, this study shows
that male gender was a determinant of treatment failure. This
is consistent with findings from Brazil, but was contrary to
observations in Uganda and Egypt [7,9,10]. This suggests that
male smear-positive TB patients need to be monitored closely
for improved adherence during TB treatment.
A positive sputum smear at 2 months of TB treatment was
found to be a strong determinant of treatment failure in this
study. This is in agreement with findings in Peru and Uganda
[9,16]. This is an important observation since sputum smear
microscopy after two months is routinely carried out in the
national TB programs. Thus, TB control programs may use
individuals classified as having persistent smear positivity
after two months of treatment to identify patients at-risk of
treatment failure who may benefit from interventions for
the prevention of treatment failure. A study in Peru found
that 93.8% of culture-positive TB patients with treatment fail-
ure had active pulmonary multidrug-resistant TB [6]. Thus,
patients found to have persistent smear positivity after two
months of treatment should be investigated further using
sputum culture and be treated further based on drug sensitiv-
ity testing.
This study also found that previous treatment for TB was a
determinant for treatment failure. The current national
guidelines recommend that previously treated patients un-
dergo retreatment with the same drugs with the addition of
streptomycin in the first two months [12]. As retreatment fail-
ure is most common among patients who had a failed initial
treatment [17], this underscores the need for further investi-
gation for the presence drug-resistant TB among all previ-
ously treated TB patients in Nigeria and other developing
countries, and to treat them based on drug susceptibility test-
ing. Other factors found to predict the occurrence of TBwho were smear positive at entry (n = 985).
At 2 months n (%) At 5 months n (%)
187 (19) 25 (2.5)
798 (81) 960 (97.5)
985 (100) 985 (100)
Table 3 – Analysis of demographic and clinical factors associated with treatment failure during anti-tuberculosis therapy in
Ebonyi State, Nigeria 2011–2012.
Characteristics Failure (N = 25) n (%) Cured (N = 789) n (%) p value
Age (years) 0.001
640 12 (48) 574 (72)
>40 13 (52) 223 (28)
Gender 0.04
Female 5 (20) 321 (40.3)
Male 20 (80) 476 (59.7)
Residence 0.7
Urban 8 (32) 225 (28.2)
Rural 17 (68) 572 (71.8)
Facility 0.53
Public 3 (12) 67 (8.4)
Private 22 (88) 730 (91.6)
Classification 0.045*
New 21 (84) 755 (94.7)
Previously treated 4 (16) 42 (5.3)
Regimen 0.17
2RHZE/6EH 16 (64) 401 (50.3)
2RHZE/4RH 9 (36) 396 (49.7)
Positive sputum smear at 2 months <0.001
Yes 23 (92) 147 (18.4)
No 2 (8) 650 (81.6)
HIV Status 0.18
Positive 5 (20) 91 (11.4)
Negative 20 (80) 706 (88.6)
P* = Fisher’s exact was used.
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treatment, deficient health education of patients about TB
disease, poor patient knowledge regarding the disease, and
diabetes mellitus as a co-morbid condition [7–10,18]. These
need to be evaluated in future studies.
This study had some limitations. The data was retro-
spectively collected from TB treatment registers. This study
does not have additional data to confirm or refute the find-
ings. In addition, there is no information on participants’
knowledge of TB, TB treatment adherence, quality of educa-
tion given the patient, co-morbid conditions like diabetes
mellitus, and anti-TB drug side effects; these factors may
affect TB treatment outcome. A qualitative study among pa-
tients who failed TB treatment will improve upon these
limitations.Conclusion
This study showed that the treatment failure rate among
smear-positive TB patients is low in Nigeria, and its determi-
nants are older age, male gender, previous TB treatment and
persistent smear positivity after two months of treatment. TB
control efforts in resource-constrained settings should target
reducing TB treatment failure. This may require additional
interventions like community and patient education to im-
prove knowledge about TB, and sputum culture and drug sen-
sitivity testing for individuals previously treated for TB orwith persistent smear positivity after two months of
treatment.
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